Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TEPEZZA (teprotumumab-trbw by Quarter
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%) (%)
Amgen TEPEZZA (teprotumumab-trbw: 14.0% in Q2 2026, up 9.0 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| TEPEZZA ® | 520 | 56 | 576 | 505 | 14%”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14.0% | +9.0 pts | Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 29.0% | +39.0 pts | Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | -1.0% | -4.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 15.0% | – | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 5.0% | – | Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | -10.0% | – | Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 3.0% | – | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Amgen TEPEZZA (teprotumumab-trbw (%), quarterly Q4 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tepezza-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.